Depression Screening in Dermatology-Think Isotretinoin.
Schrom Kory Patrick; Mostow Eliot N; Nagy Terri
JAMA dermatology
2018
2018-05
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1001/jamadermatol.2018.0085" target="_blank" rel="noreferrer noopener">10.1001/jamadermatol.2018.0085</a>
Depression screening using health questionnaires in patients receiving oral isotretinoin for acne vulgaris.
*Surveys and Questionnaires; Acne Vulgaris – Drug Therapy; Acne Vulgaris/drug therapy; Administration; depression; Depression – Diagnosis; Depression – Etiology; Depression/*diagnosis/etiology; Humans; iPLEDGE; isotretinoin; Isotretinoin – Adverse Effects; Isotretinoin – Therapeutic Use; Isotretinoin/*adverse effects/therapeutic use; Oral; patient health questionnaire-2; patient health questionnaire-9; Questionnaires; screening; suicidal ideation; Suicidal Ideation
Isotretinoin is used to treat severe and recalcitrant acne. Possible side effects include depression, suicide, and suicidal ideation; however, other studies suggest isotretinoin may improve mood and quality of life. Although iPLEDGE consenting warns about the risk of depression and suicidal ideation, there is no recommendation for screening tools. The patient health questionnaire-2 and the patient health questionnaire-9 are validated instruments that enable dermatologists to efficiently screen for depression before and after isotretinoin is initiated.
Schrom Kory; Nagy Terri; Mostow Eliot
Journal of the American Academy of Dermatology
2016
2016-07
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
<a href="http://doi.org/10.1016/j.jaad.2016.02.1148" target="_blank" rel="noreferrer noopener">10.1016/j.jaad.2016.02.1148</a>